Cytokinetics/$CYTK
1D1W1MYTD1Y5YMAX
Capital at risk
About Cytokinetics
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
- Ticker
- $CYTK
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 673
- Headquarters
- South San Francisco, United States
- Website
- www.cytokinetics.com
Cytokinetics Metrics
BasicAdvanced
$9.6B
-
-$7.18
0.38
-
Price and volume
Market cap
$9.6B
Beta
0.38
52-week high
$88.31
52-week low
$47.22
Average daily volume
1.9M
Financial strength
Current ratio
6.661
Quick ratio
6.56
Long term debt to equity
-7.755
Total debt to equity
-8.287
Interest coverage (TTM)
-5.67%
Profitability
EBITDA (TTM)
-695.362
Gross margin (TTM)
-498.65%
Net profit margin (TTM)
-1,321.12%
Operating margin (TTM)
-1,046.12%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-28.09%
Return on equity (TTM)
329.76%
Valuation
Price to revenue (TTM)
127.629
Price to book
-55.5
Price to tangible book (TTM)
-55.5
Price to free cash flow (TTM)
-14.872
Free cash flow yield (TTM)
-6.72%
Free cash flow per share (TTM)
-4.666
Growth
Revenue change (TTM)
-21.07%
Earnings per share change (TTM)
40.34%
3-year revenue growth (CAGR)
89.45%
10-year revenue growth (CAGR)
7.80%
3-year earnings per share growth (CAGR)
8.09%
10-year earnings per share growth (CAGR)
20.90%
What the Analysts think about Cytokinetics
Analyst ratings (Buy, Hold, Sell) for Cytokinetics stock.
Analyst projections of the future price of Cytokinetics stock.
Bulls say / Bears say
Cytokinetics reported positive results from the pivotal Phase 3 ACACIA-HCM trial of aficamten in non-obstructive HCM, meeting both co-primary endpoints and driving shares up over 21% pre-market (Reuters)
Following European Commission approval in February 2026, Cytokinetics launched MYQORZO (aficamten) in Germany in June, marking its first commercial availability in the EU and establishing a platform for further international expansion (Reuters)
On July 30, 2026 the UK’s MHRA granted MYQORZO marketing authorisation and NICE recommended it for NHS reimbursement, opening access to an estimated 6,600 eligible UK patients (Reuters)
Cytokinetics’ share price dipped 1.1% after the company sold approximately 9.86 million new shares at $71 each in a May follow-on offering, diluting existing shareholders and highlighting funding needs for its commercial launch (Reuters)
Total revenues for Q2 2026 fell to $28.6 million from $66.8 million a year earlier as license and milestone income dropped to zero, underscoring the company’s reliance on one-time partnership payments (Reuters)
Competition remains intense in obstructive HCM, where Bristol Myers’ Camzyos continues to gain market share and reported double-digit growth in the first quarter, potentially limiting MYQORZO’s uptake (Bloomberg)
Data summarised monthly by Lightyear AI. Last updated on 28 Aug 2026.
Cytokinetics Financial Performance
Revenues and expenses
Cytokinetics Earnings Performance
Company profitability
Upcoming events
No upcoming events
Cytokinetics News
AllArticlesVideos
Funds containing Cytokinetics
AllUSDGBPEUR
Fund name | Fund size | $CYTK weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.64% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.64% |
iShares Ageing Population€AGED | €822M | 0.48% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.30% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.27% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.